title: Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
abstract: In this study 11 patients with mild Alzheimer's disease (AD) were treated with the cholinesterase inhibitor rivastigmine (mean dose 8.6 +/- 1.3'mg) for 12 months and underwent positron emission tomography (PET) studies of cerebral glucose metabolism (CMRglc) and neuropsychological testing at baseline and after 12 months. An untreated group of 10 AD patients served as control group. While the untreated AD patients showed a significant decline of CMRglc in the temporo-parietal and frontal cortical regions after 12 months follow-up the rivastigmine-treated patients showed no decline in CMRglc in corresponding cortical brain regions. Furthermore, a significant dose-related increase in CMRglc was recorded in the right frontal association region after 12 months rivastigmine treatment. A positive correlation was observed between changes in CMRglc and several cognitive tests in patients receiving higher doses (10.5-12'mg) of rivastigmine. These results suggest a stabilization effect of rivastigmine on CMRglc in mild AD patients receiving long-term rivastigmine treatment.
authors.affiliation: Division of Molecular Neuropharmacology, Neurotec Department, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Stefanova
authors.forename: A
authors.initials: A
authors.lastname: Wall
authors.forename: O
authors.initials: O
authors.lastname: Almkvist
authors.forename: A
authors.initials: A
authors.lastname: Nilsson
authors.forename: A
authors.initials: A
authors.lastname: Forsberg
authors.forename: B
authors.initials: B
authors.lastname: Långström
authors.forename: A
authors.initials: A
authors.lastname: Nordberg
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D003071:Cognition / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009483:Neuropsychological Tests; D048448:Phenylcarbamates / Q000008:administration & dosage*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic / Q000502:physiology; D000068836:Rivastigmine; D012720:Severity of Illness Index
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; D019788:Fluorodeoxyglucose F18; D005947:Glucose; D000068836:Rivastigmine